Last reviewed · How we verify
IL-YANG Quadrivalent Influenza Vaccine
IL-YANG Quadrivalent Influenza Vaccine is a Inactivated quadrivalent influenza vaccine Biologic drug developed by Il-Yang Pharm. Co., Ltd.. It is currently in Phase 3 development for Seasonal influenza prevention in adults and children.
IL-YANG Quadrivalent Influenza Vaccine stimulates the immune system to produce antibodies against four strains of influenza virus, providing protection against seasonal flu infection.
IL-YANG Quadrivalent Influenza Vaccine stimulates the immune system to produce antibodies against four strains of influenza virus, providing protection against seasonal flu infection. Used for Seasonal influenza prevention in adults and children.
At a glance
| Generic name | IL-YANG Quadrivalent Influenza Vaccine |
|---|---|
| Sponsor | Il-Yang Pharm. Co., Ltd. |
| Drug class | Inactivated quadrivalent influenza vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
This is an inactivated quadrivalent influenza vaccine containing antigens from two influenza A strains (H1N1 and H3N2) and two influenza B strains. The vaccine triggers both humoral and cellular immune responses, enabling the body to recognize and neutralize these four circulating influenza virus strains before infection occurs.
Approved indications
- Seasonal influenza prevention in adults and children
Common side effects
- Injection site pain, redness, or swelling
- Fever
- Myalgia
- Fatigue
Key clinical trials
- Phase 3 Study to Evaluate the Immunogenicity and Safety of Inactived Split Influenza Vaccine in Healthy Korea Infants (PHASE3)
- Study to Evaluate the Immunogenicity and Safety of 'IL-YANG Quadrivalent Influenza Vaccine Inj.' (PHASE3)
- Study to Evaluate the Safety and Immunogenicity of 'IL-YANG Flu Vaccine Quadrivalent Inj' in Healthy Korean Adults (PHASE1, PHASE2)
- Immunogenicity and Safety for 'IL-YANG Quadrivalent Influenza Vaccine' in Healthy Korean Children and Adolescents (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IL-YANG Quadrivalent Influenza Vaccine CI brief — competitive landscape report
- IL-YANG Quadrivalent Influenza Vaccine updates RSS · CI watch RSS
- Il-Yang Pharm. Co., Ltd. portfolio CI
Frequently asked questions about IL-YANG Quadrivalent Influenza Vaccine
What is IL-YANG Quadrivalent Influenza Vaccine?
How does IL-YANG Quadrivalent Influenza Vaccine work?
What is IL-YANG Quadrivalent Influenza Vaccine used for?
Who makes IL-YANG Quadrivalent Influenza Vaccine?
What drug class is IL-YANG Quadrivalent Influenza Vaccine in?
What development phase is IL-YANG Quadrivalent Influenza Vaccine in?
What are the side effects of IL-YANG Quadrivalent Influenza Vaccine?
Related
- Drug class: All Inactivated quadrivalent influenza vaccine drugs
- Manufacturer: Il-Yang Pharm. Co., Ltd. — full pipeline
- Therapeutic area: All drugs in Immunology / Infectious Disease
- Indication: Drugs for Seasonal influenza prevention in adults and children
- Compare: IL-YANG Quadrivalent Influenza Vaccine vs similar drugs
- Pricing: IL-YANG Quadrivalent Influenza Vaccine cost, discount & access